Related Experiment Video
Updated: Jul 5, 2026

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
Published on: April 10, 2026
RGS4 polymorphism and response to electroconvulsive therapy in major depressive disorder
Kaija Huuhka1, Olli Kampman, Sami Anttila
1University of Tampere, Medical School, Department of Psychiatry, Tampere University Hospital, Tampere, Finland. kaija.huuhka@pshp.fi
Abstract:
We studied the association between RGS4 (rs951436) polymorphism and treatment response in electroconvulsive therapy (ECT) as well as risk of treatment-resistant depression. The study sample consisted of 119 patients with major depressive disorder (MDD) and 384 healthy control subjects. RGS4 polymorphism was not associated with treatment response in ECT or risk of MDD. According to the present data, the impact of RGS4 genotype is not decisive in major depressive disorder. The results provide preliminary data on the impact of RGS4 polymorphism in treatment response in ECT.
More Related Videos
Related Concept Videos
Electroconvulsive Therapy
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
G-protein Coupled Receptors
Antidepressant Drugs: MAOIs and Other Agents

